JAK2V617F and calreticulin mutations in recurrent venous thromboembolism: results from the EDITH prospective cohort
- 20 October 2016
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 96 (3) , 383-386
Abstract
Cancer incidence in patients with recurrent unprovoked venous thromboembolism (VTE) is much higher than after a first event, but the incidence of myeloproliferative neoplasms (MPN) in this situation is still unknown. We tested for JAK2V617F and calreticulin mutants, 372 DNA samples of patients treated for (VTR). Among these patients, 10 (2.7%) were carrying JAK2V617F mutation and none of them any of the calreticulin (CALR) mutations. Among the 19 patients who had VTE recurrence under vitamin K antagonists, 4 patients (21.0%) were positive for JAK2V617F. Despite the identification of JAK2V617F mutation, only three patients were diagnosed for MPN despite a median follow-up of 4 years. We showed that the screening for JAK2V617F not CALR mutations should be helpful in this indication especially if recurrence happened under VKA therapy.Keywords
This publication has 10 references indexed in Scilit:
- Absence of CALR mutation among a cohort of 394 unselected patients with a first episode of unprovoked venous thromboembolismThrombosis and Haemostasis, 2016
- Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosisJournal of Hepatology, 2015
- JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rateHaematologica, 2014
- Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosisHaematologica, 2014
- Somatic Mutations of Calreticulin in Myeloproliferative NeoplasmsNew England Journal of Medicine, 2013
- JAK2V617F mutation for the early diagnosis of Ph− myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysisBlood, 2009
- Systematic Review: The Trousseau Syndrome Revisited: Should We Screen Extensively for Cancer in Patients with Venous Thromboembolism?Annals of Internal Medicine, 2008
- Prevalence of the JAK2 V617F mutation is low among unselected patients with a first episode of unprovoked venous thromboembolismJournal of Thrombosis and Haemostasis, 2008
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Deep-Vein Thrombosis and the Incidence of Subsequent Symptomatic CancerNew England Journal of Medicine, 1992